Niemann-Pick type C pathogenesis and treatment: From statins to sugars

Clinical Lipidology

Volumn 5, Issue 3, 2010, Pages 387-395

  Madra, Moneek ^a   Sturley, Stephen L ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

cholesterol; neurodegeneration; Niemann Pick type C; sphingolipid

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ALPHA TOCOPHEROL; ANTIOXIDANT; CELL PROTEIN; CERAMIDE GLUCOSYLTRANSFERASE; CURCUMIN; GANGLIOSIDE; GLYCOSPHINGOLIPID; HYPOCHOLESTEROLEMIC AGENT; IBUPROFEN; LIPID; MIGLUSTAT; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN RAB9; ROSCOVITINE; STEROL; T 0910317; UBIQUINONE; UNCLASSIFIED DRUG;

DRUG TARGETING; ENDOPLASMIC RETICULUM; ENZYME REPLACEMENT; EUKARYOTE; GENE ISOLATION; GENE THERAPY; HUMAN; LIFE EXPECTANCY; LYSOSOME; MEMBRANE TRANSPORT; NERVE DEGENERATION; NIEMANN PICK DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EUKARYOTA; MURINAE;

EID: 77953868426     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.19     Document Type: Review

References (75)

1. Munkacsi A, Porto A, Sturley S: Niemann-Pick type C disease proteins: orphan transporters or membrane rheostats? Future Lipidol. 2(3), 357-367 (2007).
2. Sturley SL, Patterson MC, Balch W, Liscum L: The pathophysiology and mechanisms of NP-C disease. Biochim. Biophys. Acta 1685(1-3), 83-87 (2004).
3. Pentchev PG, Boothe AD, Kruth HS, Weintroub H, Stivers J, Brady RO: A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogenous cholesterol. J. Biol. Chem. 259(9), 5784-5791 (1984).
4. Carstea ED, Morris JA, Coleman KG et al.: Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 277(5323), 228-231 (1997).
5. Loftus SK, Morris JA, Carstea ED et al.: Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science 277(5323), 232-235 (1997).
6. Naureckiene S, Sleat DE, Lackland H et al.: Identification of HE1 as the second gene of Niemann-Pick C disease. Science 290(5500), 2298-2301 (2000).
7. Liscum L, Sturley SL: Intracellular trafficking of Niemann-Pick C proteins 1 and 2: obligate components of subcellular lipid transport. Biochim. Biophys. Acta 1685(1-3), 22-27 (2004).
8. Kwon HJ, Abi-Mosleh L, Wang ML et al.: Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137(7), 1213-1224 (2009).
9. Friedland N, Liou HL, Lobel P, Stock AM: Structure of a cholesterol-binding protein deficient in Niemann-Pick type C2 disease. Proc. Natl Acad. Sci. USA 100(5), 2512-2517 (2003).
10. Ohgami N, Ko DC, Thomas M, Scott MP, Chang CC, Chang TY: Binding between the Niemann-Pick C1 protein and a photoactivatable cholesterol analog requires a functional sterol-sensing domain. Proc. Natl Acad. Sci. USA 101(34), 12473-12478 (2004).
11. Ko DC, Binkley J, Sidow A, Scott MP: The integrity of a cholesterol-binding pocket in Niemann-Pick C2 protein is necessary to control lysosome cholesterol levels. Proc. Natl Acad. Sci. USA 100(5), 2518-2525 (2003).
12. Pentchev PG: Niemann-Pick C research from mouse to gene. Biochim. Biophys. Acta 1685(1-3), 3-7 (2004).
13. Malathi K, Higaki K, Tinkelenberg AH et al.: Mutagenesis of the putative sterol-sensing domain of yeast Niemann Pick C-related protein reveals a primordial role in subcellular sphingolipid distribution. J. Cell Biol. 164(4), 547-556 (2004).
14. Berger AC, Vanderford TH, Gernert KM, Nichols JW, Faundez V, Corbett AH: Saccharomyces cerevisiae Npc2p is a functionally conserved homologue of the human Niemann-Pick disease type C 2 protein, hNPC2. Eukaryotic cell 4(11), 1851-1862 (2005).
15. Higaki K, Almanzar-Paramio D, Sturley SL: Metazoan and microbial models of Niemann-Pick Type C disease. Biochim. Biophys. Acta 1685(1-3), 38-47 (2004).
16. Brown DE, Thrall MA, Walkley SU et al.: Feline Niemann-Pick disease type C. Am. J. Pathol. 144(6), 1412-1415 (1994).
17. Vite CH, Ding W, Bryan C et al.: Clinical, electrophysiological, and serum biochemical measures of progressive neurological and hepatic dysfunction in feline Niemann-Pick type C disease. Pediatr. Res. 64(5), 544-549 (2008).
18. Wraith JE, Baumgartner MR, Bembi B et al.: Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol. Genet. Metab. 98(1-2), 152-165 (2009).
19. Imrie J, Dasgupta S, Besley GT et al.: The natural history of Niemann-Pick disease type C in the UK. J. Inherit. Metab. Dis. 30(1), 51-59 (2007).
20. Falk T, Garver WS, Erickson RP, Wilson JM, Yool AJ: Expression of Niemann-Pick type C transcript in rodent cerebellum in vivo and in vitro. Brain Res. 839(1), 49-57 (1999).
21. Higashi Y, Murayama S, Pentchev PG, Suzuki K: Cerebellar degeneration in the Niemann-Pick type C mouse. Acta Neuropathol. 85(2), 175-184 (1993).
22. Walkley SU, Suzuki K: Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim. Biophys. Acta 1685(1-3), 48-62 (2004).
23. Patel SC, Suresh S, Kumar U et al.: Localization of Niemann-Pick C1 protein in astrocytes: implications for neuronal degeneration in Niemann-Pick type C disease. Proc. Natl Acad. Sci. USA 96(4), 1657-1662 (1999).
24. Elrick MJ, Pacheco CD, Yu T et al.: Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum. Mol. Genet. 19(5), 837-847 (2010).
25. Suzuki M, Sugimoto Y, Ohsaki Y et al.: Endosomal accumulation of Toll-like receptor 4 causes constitutive secretion of cytokines and activation of signal transducers and activators of transcription in Niemann-Pick disease type C (NPC) fibroblasts: a potential basis for glial cell activation in the NPC brain. J. Neurosci. 27(8), 1879-1891 (2007).
26. Patterson MC, Platt F: Therapy of Niemann-Pick disease, type C. Biochim. Biophys. Acta 1685(1-3), 77-82 (2004).
27. Koudinov AR, Koudinova NV: Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J. Neurol. Sci. 229-230, 233-240 (2005).
28. Patterson MC, Di Bisceglie AM, Higgins JJ et al.: The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. Neurology 43(1), 61-64 (1993).
29. Erickson RP, Garver WS, Camargo F, Hossain GS, Heidenreich RA: Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann-Pick C mice. J. Inherit. Metab. Dis. 23(1), 54-62 (2000).
30. Reid PC, Lin S, Vanier MT et al.: Partial blockage of sterol biosynthesis with a squalene synthase inhibitor in early postnatal Niemann-Pick type C npcnih null mice brains reduces neuronal cholesterol accumulation, abrogates astrogliosis, but may inhibit myelin maturation. J. Neurosci. Methods 168(1), 15-25 (2008).
31. Liu B, Li H, Repa JJ, Turley SD, Dietschy JM: Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J. Lipid Res. 49(3), 663-669 (2008).
32. Platt FM, Jeyakumar M: Substrate reduction therapy. Acta Paediatr. Suppl. 97(457), 88-93 (2008).
33. Elstein D, Hollak C, Aerts JM et al.: Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J. Inherit. Metab. Dis. 27(6), 757-766 (2004).
34. Zervas M, Somers KL, Thrall MA, Walkley SU: Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr. Biol. 11(16), 1283-1287 (2001).
35. Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther. Clin. Risk Manag. 5, 877-887 (2009).
36. Patterson MC, Vecchio D, Jacklin E et al.: Long-term miglustat therapy in children with Niemann-Pick disease type C. J. Child Neurol. 25(3), 300-305 (2010).
37. Galanaud D, Tourbah A, Lehericy S et al.: 24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy. Mol. Genet. Metab. 96(2), 55-58 (2009).
38. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE: Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 6(9), 765-772 (2007).
39. Wojtal K, Trojnar MK, Czuczwar SJ: Endogenous neuroprotective factors: neurosteroids. Pharmacol. Rep. 58(3), 335-340 (2006).
40. Mellon S, Gong W, Griffin LD: Niemann pick type C disease as a model for defects in neurosteroidogenesis. Endocr. Res. 30(4), 727-735 (2004).
41. Griffin LD, Gong W, Verot L, Mellon SH: Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat. Med. 10(7), 704-711 (2004).
42. Ahmad I, Lope-Piedrafita S, Bi X et al.: Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice. J. Neurosci. Res 82(6), 811-821 (2005).
43. Davidson CD, Ali NF, Micsenyi MC et al.: Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE 4(9), E6951 (2009).
44. Camargo F, Erickson RP, Garver WS et al.: Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci. 70(2), 131-142 (2001).
45. Liu B, Turley SD, Burns DK, Miller AM, Repa JJ, Dietschy JM: Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/-mouse. Proc. Natl Acad. Sci. USA 106(7), 2377-2382 (2009).
46. Abi-Mosleh L, Infante RE, Radhakrishnan A, Goldstein JL, Brown MS: Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells. Proc. Natl Acad. Sci. USA 106(46), 19316-19321 (2009).
47. Hsu YS, Hwu WL, Huang SF et al.: Niemann-Pick disease type C (a cellular cholesterol lipidosis) treated by bone marrow transplantation. Bone Marrow Transplant. 24(1), 103-107 (1999).
48. Bae JS, Furuya S, Ahn SJ, Yi SJ, Hirabayashi Y, Jin HK: Neuroglial activation in Niemann-Pick Type C mice is suppressed by intracerebral transplantation of bone marrow-derived mesenchymal stem cells. Neurosci Lett. 381(3), 234-236 (2005). (Pubitemid 40719163)
49. Kim SJ, Lim MS, Kang SK, Lee YS, Kang KS: Impaired functions of neural stem cells by abnormal nitric oxide-mediated signaling in an in vitro model of Niemann- Pick type C disease. Cell Res. 18(6), 686-694 (2008).
50. Ahmad I, Hunter RE, Flax JD, Snyder EY, Erickson RP: Neural stem cell implantation extends life in Niemann-Pick C1 mice. J. Appl. Genet. 48(3), 269-272 (2007).
51. Repa JJ, Li H, Frank-Cannon TC et al.: Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J. Neurosci. 27(52), 14470-14480 (2007).
52. Choudhury A, Dominguez M, Puri V et al.: Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J. Clin. Invest. 109(12), 1541-1550 (2002).
53. Narita K, Choudhury A, Dobrenis K et al.: Protein transduction of Rab9 in Niemann- Pick C cells reduces cholesterol storage. FASEB J. 19(11), 1558-1560 (2005).
54. Ganley IG, Pfeffer SR: Cholesterol accumulation sequesters Rab9 and disrupts late endosome function in NPC1-deficient cells. J. Biol. Chem. 281(26), 17890-17899 (2006).
55. Walter M, Chen FW, Tamari F, Wang R, Ioannou YA: Endosomal lipid accumulation in NPC1 leads to inhibition of PKC, hypophosphorylation of vimentin and Rab9 entrapment. Biol. Cell 101(3), 141-152 (2009).
56. Kaptzan T, West SA, Holicky EL et al.: Development of a Rab9 transgenic mouse and its ability to increase the lifespan of a murine model of Niemann-Pick type C disease. Am. J. Pathol. 174(1), 14-20 (2009).
57. Noble W, Planel E, Zehr C et al.: Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102(19), 6990-6995 (2005).
58. Bu B, Li J, Davies P, Vincent I: Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J. Neurosci. 22(15), 6515-6525 (2002).
59. Mapelli M, Massimiliano L, Crovace C et al.: Mechanism of CDK5/p25 binding by CDK inhibitors. J. Med. Chem. 48(3), 671-679 (2005).
60. Zhang M, Li J, Chakrabarty P, Bu B, Vincent I: Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am. J. Pathol. 165(3), 843-853 (2004).
61. Smith D, Wallom KL, Williams IM, Jeyakumar M, Platt FM: Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol. Dis. 36(2), 242-251 (2009).
62. Somers KL, Brown DE, Fulton R et al.: Effects of dietary cholesterol restriction in a feline model of Niemann-Pick type C disease. J. Inherit. Metab. Dis. 24(4), 427-436 (2001).
63. Li H, Repa JJ, Valasek MA et al.: Molecular, anatomical, and biochemical events associated with neurodegeneration in mice with Niemann-Pick type C disease. J. Neuropathol. Exp. Neurol. 64(4), 323-333 (2005).
64. Zampieri S, Mellon SH, Butters TD et al.: Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone. J. Cell Mol. Med. 13(9B), 3786-3796 (2009).
65. Bascunan-Castillo EC, Erickson RP, Howison CM et al.: Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann-Pick C. J. Appl. Genet. 45(4), 461-467 (2004).
66. Lloyd-Evans E, Morgan AJ, He X et al.: Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 14(11), 1247-1255 (2008).
67. Wang MS, Boddapati S, Sierks MR: Cyclodextrins promote protein aggregation posing risks for therapeutic applications. Biochem. Biophys. Res. Commun. 386(3), 526-531 (2009).
68. Vanier MT: Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen. Biochim. Biophys. Acta 750(1), 178-184 (1983).
69. Vanier MT: Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature. Neurochem. Res. 24(4), 481-489 (1999).
70. Rodriguez-Lafrasse C, Rousson R, Pentchev PG, Louisot P, Vanier MT: Free sphingoid bases in tissues from patients with type C Niemann-Pick disease and other lysosomal storage disorders. Biochim. Biophys. Acta 1226(2), 138-144 (1994).
71. Rimkunas VM, Graham MJ, Crooke RM, Liscum L: TNF-a plays a role in hepatocyte apoptosis in Niemann- Pick type C liver disease. J. Lipid Res. 50(2), 327-333 (2009).
72. Goldin E, Roff CF, Miller SP et al.: Type C Niemann-Pick disease: a murine model of the lysosomal cholesterol lipidosis accumulates sphingosine and sphinganine in liver. Biochim. Biophys. Acta 1127(3), 303-311 (1992).
73. Xie C, Turley SD, Pentchev PG, Dietschy JM: Cholesterol balance and metabolism in mice with loss of function of Niemann-Pick C protein. Am. J. Physiol. 276(2 Pt 1), E336-E344 (1999).
74. Lowenthal AC, Cummings JF, Wenger DA, Thrall MA, Wood PA, De Lahunta A: Feline sphingolipidosis resembling Niemann-Pick disease type C. Acta Neuropathol. 81(2), 189-197 (1990).
75. Centers for Disease Control and Prevention. Alzheimer's disease www.cdc.gov/aging/healthybrain/alzheimers. htm